- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07446322
Et åbent, randomiseret, multicentrisk, fase 2-studie af FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab til andenlinjebehandling af metastatisk, RAS-muteret, mikrosatellitstabil (MSS) tyktarmskræft
En åben, randomiseret, multicentrisk, fase 2-undersøgelse af FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab til andenlinjebehandling af metastatisk, RAS-muteret, mikrosatellit-stabil (MSS) tyktarmskræft
This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Approximately 60 patients will be randomized 1:1 to the following study arms:
- Arm A: FOLFIRI + bevacizumab + pelareorep
- Arm B: FOLFIRI + bevacizumab The primary endpoint is ORR as assessed by the investigator per RECIST 1.1. OS, PFS, and assessment of the safety and tolerability of the study treatment combinations are secondary endpoints. The primary endpoint analysis will be performed after all patients have had at least one tumor assessment following initiation of study treatment or have progressed. The secondary endpoint analyses will take place at EOS.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Name: Reference Study ID Number: REO 033
- Telefonnummer: +1 (858) 247-7829
- E-mail: REO-033@oncolytics.com
Studiesteder
-
-
Alabama
-
Homewood, Alabama, Forenede Stater, 35209
- Rekruttering
- Central Alabama Research
-
Kontakt:
- Lorie Syzmela
- Telefonnummer: 205-949-1907
- E-mail: lszymela@centralalabamaresearch.com
-
-
California
-
Beverly Hills, California, Forenede Stater, 90211
- Rekruttering
- Clinical Research Advisors (Beverly Hills)
-
Kontakt:
- Ali Muhammad, MD, MBA
- Telefonnummer: 310-432-8934
- E-mail: AMuhammad@bhcancercenter.com
-
Encino, California, Forenede Stater, 91316
- Rekruttering
- Clinical Research Advisors (Encino)
-
Koreatown, California, Forenede Stater, 90020
- Rekruttering
- Clinical Research Advisors (Korea Town)
-
Los Angeles, California, Forenede Stater, 90033
- Rekruttering
- Clinical Research Advisors (Downtown LA)
-
Los Angeles, California, Forenede Stater, 90048
- Rekruttering
- Clinical Research Advisors (West Hollywood)
-
West Covina, California, Forenede Stater, 91790
- Rekruttering
- Clinical Research Advisors (West Covina)
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center
-
Kontakt:
- Cheyenne Schneider
- Telefonnummer: 813-745-5166
- E-mail: Cheyenne.Schneider@moffitt.org
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30302
- Rekruttering
- Emory Winship Cancer Institute
-
Kontakt:
- Kathleen Coleman
- Telefonnummer: 404-251-1278
- E-mail: kathleen.marie.coleman@emory.edu
-
Kontakt:
- Armand Fernandez
- Telefonnummer: 404-778-8201
- E-mail: armand.falqueza.fernandez@emory.edu
-
-
Idaho
-
Post Falls, Idaho, Forenede Stater, 83854
- Rekruttering
- Beacon Cancer Center
-
Kontakt:
- Kaitie Bean
- Telefonnummer: 204 208-755-2804
- E-mail: kbean@yourbeaconclinic.com
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern Memorial Hospital
-
Kontakt:
- E-mail: clinicaltrials@northwestern.edu
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46250
- Rekruttering
- Community Health Network
-
Kontakt:
- Mindy Thacker
- Telefonnummer: 317-621-4300
- E-mail: MThacker@ecommunity.com
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48201
- Rekruttering
- Karmanos Cancer Institute
-
Kontakt:
- Taylor Brewer
- E-mail: brewert@karmanos.org
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Kontakt:
- Justin Stout
- Telefonnummer: 314-362-2582
- E-mail: justinjstout@wustl.edu
-
-
New Jersey
-
Florham Park, New Jersey, Forenede Stater, 07932
- Rekruttering
- Summit Health Cancer Center
-
Kontakt:
- Michelle Mackenzie
- Telefonnummer: 973-436-1755
- E-mail: mmackenzie@summithealth.com
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rekruttering
- Rutgers Cancer Institute
-
Kontakt:
- Christian F Misdary
- Telefonnummer: 732-735-3626
- E-mail: cm1344@cinj.rutgers.edu
-
-
Ohio
-
Canton, Ohio, Forenede Stater, 44718
- Rekruttering
- Gabrail Cancer Center
-
Kontakt:
- Carrie Smith
- Telefonnummer: 330-417-8231
- E-mail: recruitment@gabrailcancercenter.com
-
Kontakt:
- Kimberly Roby
- Telefonnummer: 227 330-492-3345
- E-mail: recruitment@gabrailcancercenter.com
-
Cincinnati, Ohio, Forenede Stater, 45219
- Rekruttering
- University of Cincinnati Medical Center
-
Colombus, Ohio, Forenede Stater, 43210
- Rekruttering
- Ohio State University
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically confirmed cancer of the colon or rectum with documented metastasis
- Measurable disease per RECIST v. 1.1
- Not candidates for curative surgery or curative radiation
- Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin
- Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
- Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
- Tumor confirmed to harbor a known RAS mutation per a standard local testing method
- ECOG performance status of 0 or 1
- Patients must have adequate hematological, renal, and hepatic function
- Female patients of childbearing potential must have a negative pregnancy test
- Life expectancy of at least 6 months
Exclusion Criteria:
- Undergone systemic chemotherapy, radiotherapy, or surgery, <4 weeks before study treatment
- Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment
- Prior treatment with irinotecan
- Symptomatic brain metastases
- Active autoimmune disease
- Receiving immunosuppressive or myelosuppressive medications
- Active, uncontrolled infections
- Known HIV infection or active hepatitis B or C that requires anti-viral treatment
- History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
- History of allergy or known hypersensitivity to any of the study drugs, study drug classes,
- Uncontrolled or severe cardiac disease
- Received any vaccine within 28 days prior to first study treatment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm A
|
Bevacizumab (5 mg/kg) IV infusion
Andre navne:
irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion pelareorep 4.5 x 10^10 TCID50 IV infusion |
|
Eksperimentel: Arm B
|
Bevacizumab (5 mg/kg) IV infusion
Andre navne:
irinotecan (180mg/m2), leucovorin 400 mg/m2 ± 5-FU (400 mg/m2) IV infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Response Rate (ORR)
Tidsramme: At week 8
|
Proportion of patients with complete response [CR], partial response [PR] assessed by the investigators and/or central reader according to RECIST v1.1 |
At week 8
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival (OS) -
Tidsramme: From the date of randomization through long term follow up at two years
|
OS defined as the time from date of randomization to death from any cause |
From the date of randomization through long term follow up at two years
|
|
Progression Free Survival (PFS)
Tidsramme: From randomization to objective progression or death from any cause, whichever occurs first, up to two years
|
Time from randomization to the date of investigator-determined objective progression (according to RECIST 1.1) or death from any cause, whichever occurs first. |
From randomization to objective progression or death from any cause, whichever occurs first, up to two years
|
|
Disease Control Rate (DCR)
Tidsramme: From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
Overall DCR, defined as the number of patients with a best overall response of CR, PR, or SD according to RECIST v. 1.1 |
From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
|
Duration of Response (DOR)
Tidsramme: From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
Time from documentation of the first CR or PR to the time of first documented evidence of progressive disease (or relapse for subjects who experience CR during the study) or death. |
From randomization to disease progression or death from any cause, whichever occurs first, up to two years
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- REO 033
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .